1. Patients receiving ATG, Campath, Basiliximab, or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment. In patients who have received these therapies as part of their conditioning regimens, 28 days must have elapsed since the final dose before VST may be given.